SCHEMBL3867984

SCHEMBL3867984

Cc1ccc2c(c1)c1cc(-c3ccccc3)c(=O)n(C)c1n2C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.45
▸ APAF1 O14727 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ IDO1 P14902 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ MCL1 Q07820 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ ADORA3 P0DMS8 1/20 0.44
▸ BCHE P06276 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ PGR P06401 1/20 0.42
▸ RORA P35398 1/20 0.42
▸ RORC P51449 1/20 0.42
▸ RORB Q92753 1/20 0.42
▸ POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385054 0.87 MAPT (0.46) KDM4EAPAF1MAPTPKMIDO1
SCHEMBL3443882 0.86 KDM4E (0.43) KDM4EAPAF1MAPTPKMIDO1
SCHEMBL2382248 0.86 MAPT (0.43) KDM4EAPAF1MAPTPKMIDO1
SCHEMBL2386185 0.86 MAOB (0.43) KDM4EAPAF1MAPTPKMIDO1
Hydrochloric Acid SCHEMBL3444526 0.85 KDM4E (0.42) KDM4EAPAF1MAPTPKMIDO1
SCHEMBL3866299 0.85 HSD17B10 (0.44) HSD17B10KDM4EMAPTHTTPOLB
SCHEMBL3443894 0.85 CYP2A6 (0.44) KDM4EAPAF1MAPTPKMIDO1
SCHEMBL5739997 0.84 KDM4E (0.41) KDM4EAPAF1MAPTPKMIDO1
SCHEMBL2384414 0.84 PADI4 (0.44) HSD17B10KDM4EAPAF1MAPTPKM
SCHEMBL2385267 0.84 KDM4E (0.43) KDM4EAPAF1MAPTPKMIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524857-B2 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents SANOFI-AVENTIS (FR) 2009-04-28 — — US claimed
US-7160895-B2 Use of pyridoindolone derivatives for the preparation of medicinal products SANOFI-AVENTIS (FR) 2007-01-09 — — US claimed
EP-1385513-B1 PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS SANOFI AVENTIS (FR) 2006-09-06 — — EP claimed
EP-1385512-B1 USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES SANOFI AVENTIS (FR) 2005-12-28 — — EP claimed
US-20050272760-A1 Use of pyridoindolone derivatives for the preparation of medicinal products SANOFI-AVENTIS (FR) 2005-12-08 — — US claimed
US-6967203-B2 Use of pyridoindolone derivatives for preparing anticancer medicines SANOFI-AVENTIS (FR) 2005-11-22 — — US claimed
US-20040122027-A1 Use of pyridoindolone derivatives for preparing anticancer medicines SANOFI (FR) 2004-06-24 — — US claimed
US-20040122036-A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents SANOFI (FR) 2004-06-24 — — US claimed
EP-1385512-A2 USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES Sanofi-Aventis (FR) 2004-02-04 — — EP claimed
EP-1385513-A1 PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS Sanofi-Aventis (FR) 2004-02-04 — — EP claimed
WO-2002087574-A2 USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES SANOFI-SYNTHELABO (FR) 2002-11-07 — — WO claimed
WO-2002087575-A1 PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS SANOFI-SYNTHELABO (FR) 2002-11-07 — — WO claimed
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
US-7524857-B2 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents SANOFI-AVENTIS (FR) 2009-04-28 — — US disclosed
US-7160895-B2 Use of pyridoindolone derivatives for the preparation of medicinal products SANOFI-AVENTIS (FR) 2007-01-09 — — US disclosed
EP-1385513-B1 PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS SANOFI AVENTIS (FR) 2006-09-06 — — EP disclosed
EP-1385512-A2 USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES Sanofi-Aventis (FR) 2004-02-04 — — EP disclosed
EP-1385513-A1 PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS Sanofi-Aventis (FR) 2004-02-04 — — EP disclosed
WO-2002087575-A1 PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS SANOFI-SYNTHELABO (FR) 2002-11-07 — — WO disclosed
WO-2002087574-A2 USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES SANOFI-SYNTHELABO (FR) 2002-11-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272760-A1 Use of pyridoindolone derivatives for the preparation of medicinal products DPYD, PNPO, ENTPD5 HSD17B10 1238/4885KDM4E 3484/4885APAF1 2072/4885
US-20040122036-A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents DPYD, DHFR, PNPO HSD17B10 763/4885KDM4E 3327/4885APAF1 569/4885
US-20040122027-A1 Use of pyridoindolone derivatives for preparing anticancer medicines DPYD, PNPO, TYMP HSD17B10 1176/4885KDM4E 3148/4885APAF1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback